<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395886</url>
  </required_header>
  <id_info>
    <org_study_id>REDNIVIN</org_study_id>
    <nct_id>NCT03395886</nct_id>
  </id_info>
  <brief_title>Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance</brief_title>
  <acronym>REDNIVIN</acronym>
  <official_title>Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance: A Prospective, Single-blinded, Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the sedation effects between remifentanil and
      dexmedetomidine in post-cardiac surgical patients who developed noninvasive ventilation (NIV)
      intolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, single-center, single-blinded study. Patients who
      receive noninvasive ventilation (NIV) in the investigators' cardiac surgical intensive care
      unit will be divided into two groups: remifentanil group and dexmedetomidine group.
      Remifentanil or dexmedetomidine will be given to the patients as needed according to the
      four-point NIV intolerance score: A score of 1 indicates a comfortable and relaxed patient
      tolerating NIV; a score of 2 indicates mild intolerance with some discomfort and occasional
      grabbing at the NIV mask; a score of 3 indicates moderate intolerance and discomfort with the
      NIV mask most of the time with frequent grabbing at the mask (sometimes pulling it off); and
      a score of 4 indicates severe NIV intolerance with agitation or/and an inability to leave the
      NIV mask in place. Participants who receive re-intubation will be recorded as 4 points. The
      investigators will compare the two groups with the NIV intolerance score at 1, 3, 6, 12, 24,
      48 and 72 hours after the initiation of the sedation regime. The investigators will also
      compare the two groups with clinical outcomes such as reintubation rate, tracheotomy rate,
      mortality, ICU length of stay etc.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(1h)</measure>
    <time_frame>1 hour after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(3h)</measure>
    <time_frame>3 hours after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(6h)</measure>
    <time_frame>6 hours after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(12h)</measure>
    <time_frame>12 hours after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(24h)</measure>
    <time_frame>24 hours after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(48h)</measure>
    <time_frame>48 hours after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>noninvasive ventilation tolerance(72h)</measure>
    <time_frame>72 hours after the initiation of sedation</time_frame>
    <description>to determine the noninvasive ventilation intolerance score and to compare the sedation effects of remifentanil and dexmiditomidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>1week after discharging from our hospital</time_frame>
    <description>ICU mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>1 week after discharging from our hospital</time_frame>
    <description>ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time</measure>
    <time_frame>1 week after discharging from our hospital</time_frame>
    <description>Mechanical ventilation time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endotracheal intubation rate</measure>
    <time_frame>1 week after discharging from our hospital</time_frame>
    <description>Endotracheal intubation rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>remifentanil group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients will receive an IV infusion of dexmiditomidine with a loading dose of 0.5-1 μg/kg/h for 10 mins, and then the dosage will be adjusted according to the sedation satisfaction. The maximum maintenance dose for dexmedetomidine is 1 μg/kg/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>The noninvasive ventilation intolerated patients will be randomized to receive remifentanil for the sedation programe.</description>
    <arm_group_label>remifentanil group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The noninvasive ventilation intolerated patients will be randomized to receive dexmeditomidine for the sedation programe.</description>
    <arm_group_label>dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients

          -  after cardiac surgery

          -  receving noninvasive ventilation

        Exclusion Criteria:

          -  age less than 18 years old

          -  coma

          -  dementia

          -  uncontrolled seizure disorder

          -  difficult expectoration

          -  pregnancy or breastfeeding

          -  intensive care delirium screening checklist score more than 4

          -  drug abuse history

          -  known allergy to opiods

          -  cardiogenic shock

          -  malignant arrhythmias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guo-wei Tu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Luo, PhD</last_name>
    <phone>021-64041990</phone>
    <phone_ext>3659</phone_ext>
    <email>luo.zhe@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan hospital, Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>noninvasive ventilation</keyword>
  <keyword>remifentanil</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>cardiac surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

